Pulse Biosciences, Inc. (PLSE)
| Market Cap | 682.70M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -49.89M |
| Shares Out | 25.22M |
| EPS (ttm) | -2.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $26.94 |
| Previous Close | $24.86 |
| Change ($) | 2.08 |
| Change (%) | 8.37% |
| Day's Open | 24.66 |
| Day's Range | 24.69 - 28.86 |
| Day's Volume | 185,455 |
| 52-Week Range | 5.23 - 28.86 |
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™)...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse StimulationTM (NPS™...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that a scie...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to p...
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2020 Results - Earnings Call Transcript
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing its Nano-Pulse Stimulation™ (NPS™) technology, today announced financi...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will re...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that clinic...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA Invest...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced the receip...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q2 2020 Results - Earnings Call Transcript
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS™) technology, today announced that th...
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q1 2020 Results - Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Darrin Uecker on Q4 2019 Results - Earnings Call Transcript
Pulse Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2019 Results - Earnings Call Transcript
Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q2 2019 Results - Earnings Call Transcript
Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q1 2019 Results - Earnings Call Transcript
Pulse BioSciences is the second instance Bob Duggan has taken the helm of a biotech that has fallen flat in an attempt to reinvigorate it.
About PLSE
Pulse Biosciences operates as a novel bioelectric medicine company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date May 18, 2016 |
| CEO Darrin R. Uecker | Employees 82 |
| Stock Exchange NASDAQ | Ticker Symbol PLSE |
Analyst Forecasts
According to one analyst, the rating for PLSE stock is "Buy" and the 12-month stock price forecast is 16.00.